Replies to post #196525 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Lykiri,

Sure looks like a pocket full of "Go big" to me. Best wishes.

[JTORENCE]

Can't believe Neil Woodford would get involved with anything that has an association with LP.

[Know-Fear]

Small world indeed.

[john1045]

Great post Lykiri, connecting the dots on relationship between all of these companies. Pretty interesting to me...on to something big here IMHO....thanks for sharing!

Message in reply to:

It’s a small world!

Linda Powers- Mark Lowdell- Neil Woodford………………..Novamune Limited- Inmune Bio- Advent Bioservices- Autolus Limited (AUTL)- Northwest Biotherapeutics- Cognate Bioservices ………...Luminus Holdings.

Woodfordfunds.

Autolus is a clinical-stage biotechnology business at the forefront of a revolution in cancer treatment. The company was founded in 2014 based on advanced cell programming technology pioneered at University College London and operates in the fast-developing and rapidly growing immuno-oncology sector.
The business focuses on developing and commercialising a novel class of immuno-oncology treatments known as CAR-T (Chimeric Antigen Receptor T-cells) therapies, which harness the power of a patient’s immune system to combat cancers.
Autolus was founded in 2014 by Syncona, who introduced us to the company. Following more than six months of due diligence, we first invested in March 2016, leading the company’s series B funding round. The position has been held in the Woodford Equity Income Fund and Woodford Patient Capital Trust ever since. The company listed on the Nasdaq stock exchange in June 2018.

https://woodfordfunds.com/funds/holdings/autolus/

INMUNE BIO, INC.
Appendix A
List of companies involved in adoptive cell therapy / immunotherapy with which Professor Lowdell has extant consultancy agreements at the commencement of this contract

Achilles Therapeutics Ltd – co-founder, shareholder, member of SAB Autolus Ltd
Avectas – chair of SAB
Cell Medica Ltd – co-founder, shareholder, member of SAB Novamune Inc – member of SAB NWBio Inc

INKmune Research and Development
Joint Development Agreement

On September 3, 2016, we entered into a joint development agreement with Novamune, Inc. (“Novamune”) (the “Development Agreement”). Novamune had previously developed and licensed technology relating to ex-vivo activation of NK cells for the treatment of cancer and other diseases. The parties agreed to exclusively collaborate on the further development of technologies related to NK cells for therapeutic applications. We will share equally in the costs related to such joint development projects and will jointly own any intellectual property developed by the joint projects, provided that Novamune shall have an exclusive royalty free license to use any such intellectual property relating to ex-vivo applications, and we shall have an exclusive royalty free license to use any such intellectual property relating to in-vivo applications. The Development Agreement is subject to Novamune investing a total of $1,250,000 in our Company, of which $350,000 has previously been advanced through a convertible note payable. The balance of $900,000 was invested on February 9, 2018 in exchange for 400,000 shares of common stock. The Development Agreement ends on September 3, 2023 unless terminated sooner. The term of the Development Agreement may be extended for one year upon the written consent of both parties. The Development Agreement may be terminated prior to the end of the term by either party in the event of a material breach by the other party of the terms of the Development Agreement, provided that the terminating party is not in breach and has first given the defaulting party written notice of termination specifying the grounds for the terminating and if after giving the defaulting party 30 days to cure the breach, the breach was not cured.

INKmune Manufacturing

We intend to contract with third parties for the manufacture of our compounds for investigational purposes, for preclinical and clinical testing and for any FDA approved products for commercial sale. Pre-clinical and clinical material for the early clinical trials with INKmune has been manufactured under the direction of Mark Lowdell and Advent Bioservices International, our strategic partner, at a licensed GMP facility. The master cell bank, working cell bank and individual product doses were completed in July 2018. This clinical material is planned for use in the Phase I/II clinical trials in ovarian cancer. If we raise adequate capital to initiate the high-risk MDS Phase I/II trials, additional working cell banks and therapeutic product will be produced from the existing master cell bank. This process takes approximately 6 months and is not anticipated to delay the initiation of the high-risk MDS Phase I/II trials. We may transfer the manufacturing to a different commercial contract manufacturing organization after completion of these Phase II studies.


Joint Development Agreement between INmune Bio, Inc. and Novamune

https://www.nasdaq.com/markets/ipos/filing.ashx?filingid=12943861#INMUNE_EX106_HTM


NOVAMUNE LIMITED
2 officers: LOWDELL, Mark William, Prof.
POWERS, Linda

https://beta.companieshouse.gov.uk/company/11323970/officers

Mark Lowdell: https://www.terrapinn.com/conference/festival-of-biologics-usa/speaker-mark-LOWDELL.stmThe

[longfellow95]

Hi Lykiri.

Did you find anything on Luminus Holdings?

I couldn't find anything when I was digging around, so can't shed any light on Luminus..

(That's enough silly puns. Ed)